Axsome Therapeutics (AXSM) Received its Third Buy in a Row

After Berenberg Bank and Guggenheim gave Axsome Therapeutics (NASDAQ: AXSM) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Vamil Divan reiterated a Buy rating on Axsome Therapeutics today and set a price target of $49.00. The company’s shares closed last Monday at $34.04.

According to, Divan is a 1-star analyst with an average return of -2.1% and a 47.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Axsome Therapeutics is a Moderate Buy with an average price target of $80.88, representing a 160.0% upside. In a report issued on April 19, BTIG also maintained a Buy rating on the stock with a $62.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Axsome Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $33.98 million. In comparison, last year the company had a GAAP net loss of $29.16 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed